Self-assembled chitosan nanofibers containing bioactive, safe and biodegradable compounds, useful as nutraceuticals or drugs.

These nanofibers are absorbed mainly at the level of the small intestine and cross the blood-brain barrier, increasing the bioavailability of bioactive compounds in different organs, including the brain, where it acts as a controlled release system (SLC). Nanofibers, as they contain antioxidant bioactive compounds, are especially useful in the treatment or prevention of neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, Huntington’s, Amyotrophic Lateral Sclerosis (ALS); as well as strokes and other diseases related to aging or associated with oxidative stress.

The increase in life expectancy of people brings with it the increase in 
neurodegenerative diseases.

Development State

The technology is laboratory-tested, including preliminary tests on animals and cell cultures.

It is in the process of validation.

Bioavailability in the brain


  • Drug to prevent and treat neurodegenerative diseases, for oral use.
  • Nutraceutical for the prevention of neurodegenerative diseases.
As nanofibres contain bioactive antioxidant compounds, they are especia- lly useful in the treatment or prevention of neurodegenerative diseases


The world’s population is aging and with this, diseases that account for the aging of the human body becoming more prevalent every day. In particular, patients with pathologies derived from neuronal cell deterioration, such as Alzheimer’s, Parkinson’s, or ALS, have become more common.

Until now, patients with these pathologies are treated with drugs that turn out to be only  palliative, given their low efficiency and bioavailability of their active ingredients, since they cannot efficiently reach their target destination, an example of this is the brain, as they do not achieve to cross the blood-brain barrier.